Article

HLA-derived peptides as novel immunosuppressives.

Stanford University School of Medicine, California 94305-5119, USA.
Nephrology Dialysis Transplantation (Impact Factor: 3.49). 06/1997; 12(5):865-8. DOI: 10.1203/00006450-199509000-00001
Source: PubMed

ABSTRACT Over the past decade the use of synthetic peptides corresponding to linear sequences of HLA molecules has progressed from a concept to a reality. These peptides are currently being evaluated in clinical trials. In animal models these peptides, given over 1 week with cyclosporin alone, induced long-term immunological tolerance (Figure 3). They may similarly induce tolerance in humans. The next major hurdle for such tolerogenic drugs, however, is to prove efficacy in clinical circumstances. Many of the drugs used to treat transplant patients today (steroids, cyclosporin, azathioprine, mycophenolate mofetil) may actually inhibit the 'active' processes of induction and maintenance of immunological tolerance. Demonstration that new drugs induce tolerance will require efficacy studies in other immune-mediated diseases in which monotherapy is feasible (such as psoriasis), before further advances can be made in the induction of transplant tolerance. In addition, rapid assays of rejection must be developed in order to reverse tolerance induction failures without graft damage or loss. Lastly, it will require heroic physicians, surgeons, and patients to make immunological tolerance a reproducible clinical reality.

Download full-text

Full-text

Available from: Alan M Krensky, Apr 23, 2014
0 Followers
 · 
58 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: New insights into the mechanisms of allorecognition and the interactions of the TCR with the MHC molecule-peptide complex on antigen presenting cells have focused attention on developing novel biological strategies to modify the alloimmune response. Peptides derived from various regions of MHC class I and II molecules and structure-based peptides have demonstrated immunomodulatory effects both in vitro and in vivo. Their binding sites and mechanisms of action are under active investigation. Trials in human transplant recipients, with an MHC class I peptide have already begun.
    Current Opinion in Immunology 11/1997; 9(5):669-75. DOI:10.1016/S0952-7915(97)80047-7 · 7.87 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The interaction of the T-cell receptor with the major histocomatibility complex (MHC)-peptide complex is central to T-cell activation. Variation in the nature of the peptide bound within the groove of the MHC molecule may result in an altered T-cell response. Because some naturally processed peptides bound within the groove of the class II MHC molecule are derived from the MHC molecules themselves, we studied the inhibitory effects of synthetic class II MHC peptides on alloimmune responses in vitro. Three peptides derived from a highly conserved region of the class II MHC alpha chains inhibited the rat mixed lymphocyte response (MLR) in a dose-dependent manner, with the human HLA-DQA1 peptide also inhibiting the human and mouse MLR. No effect was seen on mitogen-induced T-cell proliferation. HLA-DQA1 inhibited cytolytic T lymphocyte (CTL) generation in a dose-response fashion, with no reduction in preformed CTL killing, suggesting that the inhibitory effect is targeted at CD4(+) T-cell function. Cell-cycle analysis by flow cytometry showed that restimulation of primed T cells in the presence of HLA-DQA1 resulted in increased apoptosis, whereas unstimulated cells were not affected. These data demonstrate that synthetic peptides derived from highly conserved regions of the class II MHC alpha chain can alter CD4(+) T-lymphocyte alloimmune responses in vitro, and this effect is mediated by the induction of apoptosis in activated T cells.
    Journal of Clinical Investigation 04/1999; 103(6):859-67. DOI:10.1172/JCI5734 · 13.77 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the role of the indirect pathway of recognition in human allograft rejection, we have mapped the dominant T cell determinant of the HLA-DRβ1*0101 molecule presented by the DRβ1*1101 antigen. A synthetic peptide (pp 22–35) corresponding to the sequence of the dominant peptide determinant was used for testing the frequency ofin vivoactivated T cells in the graft and in the periphery. DRβ1*1101-positive patients carrying a heart allograft mismatched for the HLA-DR1 antigen showed no reactivity to pp 22–35 during quiescence. However, interleukin-2-responsive T cells, which were pp 22–35 specific, were found in the circulation prior to and at the time of acute and chronic rejection. The response ofin vivoandin vitroactivated T cells was inhibited at high concentrations of peptide 22–35. This data suggests that indirect recognition plays an important role in allograft rejection and that it can be abolished by high zone tolerance induction.
    Clinical Immunology and Immunopathology 04/1996; 78(3-78):228-235. DOI:10.1006/clin.1996.0034